Effects of Dexmedetomidine Administered Through Different Routes on Kidney Tissue in Rats With Spinal Cord Ischaemia-Reperfusion Injury

Loading...
Publication Logo

Date

2022

Journal Title

Journal ISSN

Volume Title

Publisher

Dove Medical Press Ltd

Open Access Color

GOLD

Green Open Access

Yes

OpenAIRE Downloads

OpenAIRE Views

Publicly Funded

No
Impulse
Top 10%
Influence
Average
Popularity
Top 10%

Research Projects

Journal Issue

Abstract

Background: Ischaemia-reperfusion (IR) injury, which can be encountered during surgical procedures involving the abdominal aorta, is a complex process that affects distant organs, such as the heart, liver, kidney, and lungs, as well as the lower extremities. In this study, we aimed to contribute to the limited literature by investigating the protective effect of dexmedetomidine, which was administered through different routes, on kidney tissue in rats with spinal cord IR injury.Methods: A total of 30 rats were randomly divided into five groups: control (C group), IR (IR group), IR-intraperitoneal dexmedetomidine (IRIPD group), IR-intrathecal dexmedetomidine (IRITD group), and IR-intravenous dexmedetomidine (IRIVD group). The spinal cord IR model was established. Dexmedetomidine was administered at doses of 100 mu g/kg intraperitoneally, 3 mu g/ kg intrathecally, and 9 mu g/kg intravenously. Histopathologic parameters in kidney tissue samples taken at the end of the reperfusion period and biochemical parameters in serum were evaluated.Results: When examined histopathologically, tubular dilatation was found to be significantly reduced in the IRIVD, IRITD, and IRIPD groups compared with the IR group (p = 0.012, all). Vascular vacuolization and hypertrophy were significantly decreased in the IRIVD, IRITD, and IRIPD groups compared with the IR group (p = 0.006, all). Tubular cell degeneration and necrosis were significantly reduced in the IRIVD, IRITD, and IRIPD groups compared with the IR group (p = 0.008, p = 0.08, and p = 0.030, respectively). Lymphocyte infiltration was significantly decreased in the IRIVD and IRITD groups compared with the IR group (p = 0.006 and p = 0.06, respectively). Conclusion: It was observed that dexmedetomidine administered by different routes improved the damage caused by IR in kidney histopathology. We think that the renoprotective effects of dexmedetomidine administered intravenously and intrathecally before IR in rats are greater.

Description

Dursun, Ali Dogan/0000-0001-9056-0025; Arslan, Mustafa/0000-0003-4882-5063; Sengel, Necmiye/0000-0001-8591-3658

Keywords

dexmedetomidine, ischaemia-reperfusion, intrathecal, intravenous, rat, Ischaemia–reperfusion, intrathecal, Drug Design, Development and Therapy, Spinal Cord Ischemia, dexmedetomidine; intrathecal; intravenous; ischaemia–reperfusion; rat, dexmedetomidine, RM1-950, Kidney, Rats, dexmedetomidine; ischaemia-reperfusion; intrathecal; intravenous; rat, Reperfusion Injury, intravenous, Animals, rat, Therapeutics. Pharmacology, ischaemia–reperfusion, Dexmedetomidine, Original Research

Fields of Science

0301 basic medicine, 0303 health sciences, 03 medical and health sciences

Citation

WoS Q

Q1

Scopus Q

Q1
OpenCitations Logo
OpenCitations Citation Count
10

Source

Drug Design, Development and Therapy

Volume

16

Issue

Start Page

2229

End Page

2239

Collections

PlumX Metrics
Citations

Scopus : 20

PubMed : 12

Captures

Mendeley Readers : 7

SCOPUS™ Citations

20

checked on Apr 26, 2026

Web of Science™ Citations

18

checked on Apr 26, 2026

Google Scholar Logo
Google Scholar™
OpenAlex Logo
OpenAlex FWCI
2.64

Sustainable Development Goals

SDG data is not available